Development and Application of Comprehensive Intervention Techniques for Adolescent Depression

Sponsor
First Affiliated Hospital of Zhejiang University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05945342
Collaborator
(none)
400
1
5
29.9
13.4

Study Details

Study Description

Brief Summary

In order to realize the early identification, risk warning and comprehensive intervention of adolescent depression, this project carried out research on the diagnosis platform of adolescent depression, the construction of suicide risk warning and evaluation system, the development of interpersonal psychotherapy technology (IPT-A), and the rapid intervention technology of robotic navigation repetitive transcranial magnetic stimulation (rTMS). Through the extraction of psychological, peripheral and central biological characteristics of adolescent depression and the establishment of a diagnostic platform, combined with artificial neural network to achieve efficient and accurate identification of high risk of suicide population. Antidepressant drugs combined with psychotherapy and antidepressant drugs combined with rTMS physical therapy were used to improve the clinical effective rate and recovery rate. Finally, a comprehensive prevention and control technology suitable for hospitals, schools and families to participate in.

Condition or Disease Intervention/Treatment Phase
  • Drug: Fluoxetine
  • Other: Interpersonal Psychotherapy for Adolescent
  • Other: Fluoxetine combined with psychotherapy
  • Other: Fluoxetine combined with rTMS
  • Drug: Fluoxetine combined with sham rTMS
N/A

Detailed Description

  1. The interaction of symptoms, psychological indicators (including environmental risk factors and neuropsychology), peripheral biology (peripheral neuroimmunity, neurotrophic factors and neuroendocrine related indicators), central biological indicators (neuroimaging, near-infrared functional brain imaging) and brain-derived exosome detection in peripheral blood was constructed based on artificial intelligence technology The network of clinical diagnosis platform, and according to the high and low suicide risk classification of deep learning, the establishment of adolescent depression early identification and suicide risk warning system.

  2. To develop a simplified interpersonal psychotherapy technique (IPT-A) for adolescent depression.

  3. Research and development of rTMS neuroregulation technology for precise positioning of robot navigation in adolescent depression.

  4. Construct comprehensive intervention models and efficacy prediction models for adolescent depression, such as drug combined with psychology and drug combined with physical therapy, and promote and demonstrate the application.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Research and Application of Key Technologies for Early Identification, Risk Warning and Comprehensive Intervention of Adolescent Depression
Actual Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Jun 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Simple Medication

Fluoxetine alone treatment

Drug: Fluoxetine
The US Food and Drug Administration(FDA) has only approved fluoxetine and escitalopram for the treatment of adolescent depression

Active Comparator: Simple Psychotherapy

Simple interpersonal psychotherapy group

Other: Interpersonal Psychotherapy for Adolescent
Interpersonal Psychotherapy for Adolescent(IPT-A), A modified version of interpersonal psychotherapy, is shorter than the standard therapy duration (12-16 sessions), with a total of eight sessions, retaining the structure of the standard IPT but employing a series of strategies to extract the most important components to speed up the time process.

Experimental: Medication combined with psychotherapy

Medication combined with interpersonal psychotherapy

Other: Fluoxetine combined with psychotherapy
The subjects received adolescent interpersonal psychotherapy for adolescent(IPT-A) while taking medication

Experimental: Medication combined with physical therapy group

Medication combined with robotic navigational repetitive transcranial magnetic stimulation

Other: Fluoxetine combined with rTMS
The subjects received Robotic navigational repetitive transcranial magnetic stimulation while taking medication

Sham Comparator: Medication combined with sham physical therapy group

Medication combined with sham robotic navigational repetitive transcranial magnetic stimulation

Drug: Fluoxetine combined with sham rTMS
The subjects received sham Robotic navigational repetitive transcranial magnetic stimulation while taking medication

Outcome Measures

Primary Outcome Measures

  1. Score of Child Depression Rating Scale-Revised [Baseline, 2-week, 4-week, 8-week]

    For clinical depression symptom assessment

  2. Score of Beck Scale for Suicide Ideation [Baseline, 2-week, 4-week, 8-week]

    For the quantitative assessment of suicidal ideation

  3. Score of Iowa Gambling Task [Baseline, 2-week, 8-week]

    The simulation of the real decision situation is a kind of decision making task in the fuzzy situation accompanied by corresponding rewards and punishments

  4. Score of THINC-it test [Baseline, 2-week, 8-week]

    The test includes Spotter, Symbol check, Codebreaker, Trails, and the 5-item Depression Cognitive Deficit Questionnaire (PDQ-5-D). It is used to assess working memory, executive function and attention

  5. Hypocretin [Baseline, 2-week, 8-week]

    Hypocretin is a neurotransmitter that regulates wakefulness and appetite

  6. Endocannabinoid [Baseline, 2-week, 8-week]

    Endocannabinoid play an important role in regulating many functions in the body, including the inflammatory system, immune function, sleep, appetite, digestion, pain receptors, hormones, reproductive function and memory

  7. Neuroimmune-related factors [Baseline, 2-week, 8-week]

    Such as IL-lβ、IL-6、TNF-α

  8. Neurotrophic pathway related factors [Baseline, 2-week, 8-week]

    Such as BDNF、VGF、TrkB、tPA

  9. Near infrared functional imaging of the brain [Baseline, 2-week, 8-week]

    Near infrared functional brain imaging can reflect the activation degree of brain function and functional connectivity of brain by detecting the concentration changes of oxygenated hemoglobin and deoxygenated hemoglobin in the target brain area.

  10. Change in working memory test scores after intervention [Baseline, 2-week, 8-week, 24-week]

    The working memory test consists of two parts, which measure the breadth and accuracy of working memory respectively. The breadth of working memory will be tested using the operating span experiment, as the accuracy of working memory will be tested using the Memory Orientation experiment

  11. Change in three component test of executive function scores after intervention [Baseline, 2-week, 8-week, 24-week]

    The three component tests of executive function were one-backward test, anti-saccade and shifting test respectively.In the one-backward test, subjects need to memorize letters while counting numbers, scoring them according to the accuracy of the alphabetic memory order; The anti-saccade test asks subjects to react to a flash of arrows (0.5 seconds) by selecting the direction they see on a keyboard;The shifting test asked subjects to select a forward or reverse feedback key depending on where the icon appeared

  12. TMS-Evoked potential [Baseline, 2-week, 8-week]

    The integration of transcranial magnetic stimulation (TMS) and electroencephalography (EEG) is a valuable method for directly probing excitability, connectivity and oscillatory dynamics of regions throughout the brain. Offering in depth measurement of cortical reactivity, TMS-EEG allows the evaluation of TMS-evoked components that may act as a marker for cortical excitation and inhibition.

  13. Magnetic Resonance Imaging [Baseline, 2-week, 8-week]

    Functional magnetic resonance brain imaging can reflect the functional and metabolic information of neurons before morphological changes

Secondary Outcome Measures

  1. Score of 24-item Hamilton Depression Rating Scale [Baseline, 2-week, 4-week, 8-week]

    For clinical depression symptom assessment

  2. Ottawa Self-injury Questionnaire [Baseline, 2-week, 4-week, 8-week]

    To evaluate the situation of NSSI among adolescents

  3. Score of Childhood Trauma Questionnaire [Baseline]

    Used to assess traumatic experiences in childhood

Eligibility Criteria

Criteria

Ages Eligible for Study:
12 Years to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Sign a written informed consent to participate in the trial and receive treatment;

  • Meet the diagnostic criteria of depression in DSM-5, and have no psychotic characteristics;

  • Child Depression Rating Scale-Revised (CRs-R)≥40 points;

  • 24 Hamilton Depression Scale (HAMD-24) scores ≥20;

  • First or recurrent depressive episode, not received antidepressant drugs and systematic psychotherapy in recent 2 months;

  • The Han nationality, right hand

Exclusion Criteria:
  • Have other mental disorders, or have a history of other mental disorders, such as attention deficit movement disorder, autism, and developmental retardation;

  • Patients with current infections, trauma, autoimmune diseases, other unstable medical conditions, or who are receiving hormone therapy;

  • Patients with a history of craniocerebral injury and coma;

  • A family history of bipolar disorder, seizures, or epilepsy;

  • Those who had substance abuse or dependence within the first three months of enrollment;

  • Patients with contraindications for MRI examination such as metal foreign body in the skull or abnormal brain structure found in MRI examination.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The First Affiliated Hospital of Zhejiang University Hangzhou Zhejiang China 310009

Sponsors and Collaborators

  • First Affiliated Hospital of Zhejiang University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
First Affiliated Hospital of Zhejiang University
ClinicalTrials.gov Identifier:
NCT05945342
Other Study ID Numbers:
  • IIT2023510
First Posted:
Jul 14, 2023
Last Update Posted:
Jul 14, 2023
Last Verified:
Jan 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 14, 2023